US equities
|
NVDA
$215.30
▼-2.71%
MU
$859.94
▼-5.93%
SNDK
$1,278.01
▼-8.93%
SPCX
$144.22
▼-5.21%
AMD
$535.43
▼-6.20%
TSM
$413.01
▼-3.95%
INTC
$93.25
▼-4.97%
AAPL
$345.82
▲+0.83%
NVDA
$215.30
▼-2.71%
MU
$859.94
▼-5.93%
SNDK
$1,278.01
▼-8.93%
SPCX
$144.22
▼-5.21%
AMD
$535.43
▼-6.20%
TSM
$413.01
▼-3.95%
INTC
$93.25
▼-4.97%
AAPL
$345.82
▲+0.83%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Amylyx Pharmaceuticals, Inc. - Common Stock
(NQ:
AMLX
)
27.57
+0.54 (+2.00%)
Delayed Quote
Updated: 9:39 AM EDT, Oct 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amylyx Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
October 06, 2026
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment
↗
October 03, 2026
Amylyx Pharmaceuticals (NASDAQ:AMLX) said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to...
Via
MarketBeat
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
September 23, 2026
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
September 08, 2026
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals (NASDAQ:AMLX) Misses on Q2 Bottom Line as LUCIDITY Readout Looms
↗
August 06, 2026
Via
Chartmill
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
↗
September 01, 2026
Amylyx looks promising, but a pullback would improve the opportunity.
Via
The Motley Fool
Should Eli Lilly Investors Be Worried About a Threat From Amylyx?
↗
August 30, 2026
Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.
Via
The Motley Fool
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week
↗
August 21, 2026
The biotech delivered excellent news from the laboratory.
Via
The Motley Fool
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
August 19, 2026
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Why Amylyx Pharmaceuticals Stock Skyrocketed Today
↗
August 18, 2026
GLP-1 drugs aren't just for weight loss.
Via
The Motley Fool
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock
August 18, 2026
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
August 18, 2026
Gainers AIxCrypto Hldgs (NASDAQ:AIXC) stock increased by 132.0% to $1.65 during Tuesday's regular session. The market value of their outstanding shares is at $14.3 million. Amylyx Pharmaceuticals...
Via
Benzinga
Amylyx Phase III Avexitide Trial Cuts Severe Hypoglycemic Events 55%
↗
August 18, 2026
Amylyx Pharmaceuticals (NASDAQ:AMLX) said its Phase III LUCIDITY trial of avexitide met its primary endpoint, reducing the composite rate of clinically significant hypoglycemic events by 55% versus...
Via
MarketBeat
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
August 18, 2026
Gainers Amylyx Pharmaceuticals (NASDAQ:AMLX) stock increased by 27.5% to $27.32 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.3 billion. bioAffinity...
Via
Benzinga
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
August 18, 2026
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026
August 17, 2026
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx (AMLX) Q2 2026 Earnings Call Transcript
↗
August 13, 2026
LUCIDITY data readout expected late August or early September.
Via
The Motley Fool
Topics
Earnings
Amylyx Pharmaceuticals Q2 Earnings Call Highlights
↗
August 06, 2026
Amylyx Pharmaceuticals (NASDAQ:AMLX) said its pivotal Phase III LUCIDITY trial of avexitide in post-bariatric hypoglycemia, or PBH, has completed final patient visits, with top-line data expected in...
Via
MarketBeat
Topics
Earnings
Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results
August 06, 2026
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
August 03, 2026
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026
June 23, 2026
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape
↗
June 10, 2026
Amylyx Pharmaceuticals (NASDAQ:AMLX) Co-Chief Executive Officer Justin Klee said the company is preparing for a key Phase 3 readout for avexitide, its lead program for post-bariatric hypoglycemia,...
Via
MarketBeat
Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026
June 08, 2026
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
What to Know About This Fund's $10 Million Bet on Gold Miners
↗
May 24, 2026
ASA Gold and Precious Metals Limited targets global mining equities, specializing in gold, silver, and other precious minerals investments.
Via
The Motley Fool
Topics
Economy
Amylyx Stock: Why the Full Pipeline Story Matters
↗
May 24, 2026
Amylyx stock has surged on pipeline progress, but investors should understand the risks and long-term catalysts driving AMLX shares
Via
MarketBeat
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares
↗
May 19, 2026
This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs.
Via
The Motley Fool
Topics
Regulatory Compliance
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors
↗
May 19, 2026
Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation
May 15, 2026
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus
↗
May 14, 2026
Amylyx Pharmaceuticals (NASDAQ:AMLX) is preparing for a pivotal Phase 3 readout for AVEXITIDE, its lead asset for post-bariatric hypoglycemia, or PBH, with data from the LUCIDITY trial expected in the...
Via
MarketBeat
Amylyx (AMLX) Q1 2026 Earnings Transcript
↗
May 08, 2026
Amylyx (AMLX) Q1 2026 Earnings Transcript
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
